Akshay Sharma, MBBS, on Overcoming Challenges for Administration of Ex-Vivo SCD Gene Therapy
The attending physician and assistant member of bone marrow transplantation and cellular therapy at St Jude Children’s Research Hospital also discussed hurdles to accessibility for SCD gene therapy.
“Hopefully, in the next 5 to 10 years, we will have figured out all these things: how to mobilize cells better and how to give cells with lesser toxicity. I think all of these things will improve the safety profile of gene therapy for patients with SCD.”
On December 8, 2023, the FDA approved Vertex Pharmaceuticals' and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel, marketed as Casgevy) and bluebird bio’s lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia) for the treatment of sickle cell disease (SCD). Both exa-cel and lovo-cel are ex-vivo autologous gene therapies, and are manufactured and administered in a multistep process. Patients first need to receive an agent, plerixafor, to mobilize their hematopoietic stem cells to the peripheral blood for collection. Collecting an adequate number of cells for manufacture of the gene therapy product can take several days. After the cells are genetically modified outside the body, patients also need to undergo myeloablation to wipe out their unmodified hematopoietic stem cells before they can receive the modified cells. This is accomplished with the use of chemotherapy in the form of busulfan, which carries a number of short-term risks, such as immunosuppression and ulcers, and long-term risks, such as secondary malignancies.
Following his presentation on the new SCD gene therapies at
REFERENCES
1. Sharma A, Sheehan V, Shenoy S. Tandem Thursday breakfast symposium: the evolving paradigm of sickle cell disease management. Presented at: 2024 Tandem Meetings, February 21-24, San Antonio, Texas. Session #S-B1.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025